Meiragtx Holdings Plc shares rose 3.5% in pre-market trading.
Meiragtx Holdings Plc experienced a 3.5% rise in pre-market trading following a strategic investment of up to $400 million from Oberland Capital. This capital infusion is expected to bolster the company's R&D capabilities and operational funding, leading to increased investor confidence. The investment also suggests potential industry resources and strategic synergies that could further drive Meiragtx's gene therapy explorations.
MGTX (NASDAQ): Proposed resale notice for 27,659 ordinary shares
MGTX (MeiraGTx Holdings plc) has submitted a Form 144 notice indicating a proposed sale of 27,659 ordinary shares with a gross value of $368,694.47 through Fidelity Brokerage Services LLC, referenced to July 7, 2026, on NASDAQ. The filing also notes a previous sale by Stuart Naylor of 27,661 shares on April 7, 2026, for $258,874.75. This Form 144 serves to notify the market of intent to sell insider-held shares, with the final execution subject to market conditions.
MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec
MeiraGTx, a clinical-stage genetic medicines company, has secured a strategic investment of up to $400 million from Oberland Capital Management LLC. This funding, comprising up to $375 million in non-dilutive capital and up to $25 million in equity, will support the development and commercialization of its late-stage programs, including AAV2-hAQP1 for radiation-induced xerostomia and botaretigene sparoparvovec for X-linked retinitis pigmentosa. Oberland Capital will receive low single-digit capped royalties on net sales of these products upon regulatory approval, reflecting confidence in their commercial potential and MeiraGTx's pipeline.
MeiraGTx wins $400M investment from Oberland Capital
MeiraGTx Holdings plc secured up to $400 million in funding from Oberland Capital Management LLC. This investment will support the development of MeiraGTx's gene therapy candidates. Following the announcement, the company's shares rose about 7% in premarket trading.
MeiraGTx (Nasdaq: MGTX) lands $400M Oberland royalty and equity deal
MeiraGTx Holdings plc secured a strategic financing deal totaling up to $400 million with Oberland Capital. This includes up to $375 million in non-dilutive royalty notes tied to the net sales of three late-stage gene therapies (AAV-AIPL1, AAV2-hAQP1, and bota-vec) and an equity investment of up to $25 million. The company utilized this funding to fully repay its outstanding Perceptive notes without penalties, aiming to finance advanced gene therapy programs and support commercialization efforts.
MeiraGTx Secures Up To $375 Million Royalty Financing, Adds $10 Million Equity, Retires Perceptive Debt
MeiraGTx has successfully completed a significant financing and refinancing package. The company secured up to $375 million in royalty-backed funding from Oberland Capital, raised $10 million through a private share placement, and retired its Perceptive Credit notes without penalties. This strategic move aims to strengthen liquidity and simplify its capital structure.
MGTX - MeiraGTx Holdings plc Options
This article provides a detailed financial overview of MeiraGTx Holdings plc (MGTX), including its market capitalization, enterprise value, income, sales, and various financial ratios. It also lists key performance indicators such as EPS, sales growth, insider and institutional ownership, and stock performance over different periods. The data indicates strong recent performance and growth, alongside information on options availability and short interest.
MeiraGTx Holdings stock hits 52-week high at 13.72 USD By Investing.com
MeiraGTx Holdings stock reached a new 52-week high of $13.71, marking an 85% total return over the past year. Analysts have revised earnings upwards, and recent developments include the election of new directors and a strategic collaboration with Hologen Limited for gene therapies. Despite being currently unprofitable, investor confidence is high, reflected in increased price targets from Piper Sandler, RBC Capital, and H.C. Wainwright.
MeiraGTx Holdings stock hits 52-week high at 13.72 USD
MeiraGTx Holdings PLC stock reached a 52-week high of $13.72, reflecting an 85% total return over the past year. Despite being noted as overvalued by InvestingPro, analysts have revised earnings upwards, driven by durable data for their xerostomia treatment, the reacquisition of bota-vec, and strategic collaborations in gene therapy. This surge in stock price highlights strong investor confidence in the company's therapeutic programs and future growth potential.
Price to book forward of MeiraGTx Holdings plc – NASDAQ:MGTX
This article provides access to the "Price to book forward" financial metric for MeiraGTx Holdings plc (NASDAQ: MGTX) on TradingView. It highlights that the market for MGTX was closed at the time of viewing and that no trades were recorded. The content primarily serves as a gateway to financial data and trading tools for the company.
Price to earnings forward of MeiraGTx Holdings plc – NASDAQ:MGTX
The article focuses on the "Price to earnings forward" metric for MeiraGTx Holdings plc (NASDAQ: MGTX), as presented on TradingView. It indicates that the market was closed at the time of viewing, with no trades having occurred. The content primarily displays navigation and boilerplate information from the TradingView platform.
Enterprise value to revenue forward of MeiraGTx Holdings plc – NASDAQ:MGTX
This page provides financial information for MeiraGTx Holdings plc (NASDAQ: MGTX), specifically focusing on its enterprise value to revenue forward. The content is presented as a financial data point from TradingView, indicating a key metric for the biotechnology company. It's concise and primarily serves as a data presentation rather than an analytical article.
MeiraGTx Holdings stock hits 52-week high at 13.72 USD By Investing.com
MeiraGTx Holdings stock recently hit a 52-week high of $13.71, reflecting an 85% total return over the past year. Despite being unprofitable, analysts have revised earnings upwards, and the company has announced strategic collaborations and board elections. Analyst price targets range from $20 to $30, maintaining positive ratings.
MeiraGTx Holdings stock hits 52-week high at 13.72 USD By Investing.com
MeiraGTx Holdings PLC stock reached a new 52-week high of $13.71, achieving an 85% total return over the past year. Despite being deemed overvalued by InvestingPro, analysts anticipate increased earnings, and the company recently elected new directors and expanded its gene therapy collaborations for Parkinson's and genetic obesity. Several analysts have raised their price targets for MeiraGTx based on positive data and strategic developments.
(MGTX) Risk Channels and Responsive Allocation
Quantitative Research Desk has provided an analysis of Meiragtx Holdings Plc (NASDAQ: MGTX), indicating strong sentiment across all time horizons and compelling upside potential due to no resistance levels above the current price. The report outlines institutional trading strategies including position trading, momentum breakout, and risk hedging, with specific entry, target, and stop-loss levels. These strategies are supported by multi-timeframe signal analysis and AI-generated signals for risk management.
Form 4 MeiraGTx Holdings PLC For: 29 June By Investing.com
This article announces the filing of Form 4 for MeiraGTx Holdings PLC (MGTX) for June 29. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's securities by an insider. The brief article, published by Investing.com, indicates a potential insider transaction or change in holdings for the company.
MeiraGTx (NASDAQ: MGTX) awards 980,000 RSUs to its CFO & COO
MeiraGTx (NASDAQ: MGTX) has awarded 980,000 Restricted Share Units (RSUs) to its CFO & COO, Richard Giroux. These RSUs will vest over four years, with 50% vesting on the second anniversary of the grant date and 25% on the third and fourth anniversaries. This grant serves as a form of equity compensation, aligning executive incentives with the company's long-term performance.
MeiraGTx (MGTX) awards 100,000 RSUs to Chief Medical Officer
MeiraGTx Holdings plc (MGTX) has granted 100,000 restricted share units (RSUs) to its Chief Medical Officer, Robert K. Zeldin. These RSUs will convert into ordinary shares upon vesting, with a schedule of 50% vesting on the second anniversary and 25% on each of the third and fourth anniversaries of the grant date. This transaction is considered neutral in sentiment and aims to align executive incentives with company performance.
MeiraGTx (MGTX) CEO Alexandria Forbes receives 980,000 RSU equity grant
MeiraGTx Holdings plc's President and CEO, Alexandria Forbes, was granted 980,000 restricted share units (RSUs) on June 25, 2026. These RSUs convert into ordinary shares upon vesting, with a vesting schedule of 50% on the second anniversary and 25% on the third and fourth anniversaries of the grant date. This grant, with a price of $0.00 per unit, aligns her compensation with the company’s long-term share performance.
MeiraGTx (MGTX) awards 70,000 Restricted Share Units to key executive
MeiraGTx Holdings plc (MGTX) has granted 70,000 Restricted Share Units (RSUs) to Stuart Naylor, its Chief Scientific Officer of Ophthalmology. These RSUs convert into ordinary shares upon vesting, with 50% vesting on the second anniversary of the grant date, and 25% each on the third and fourth anniversaries. This grant structure aims to align executive incentives with the company's long-term performance.
MeiraGTx (MGTX) General Counsel granted 100,000 restricted share units
MeiraGTx Holdings plc reported that its General Counsel, Robert J. Wollin, received a grant of 100,000 restricted share units (RSUs). These RSUs will convert to ordinary shares upon vesting, with 50% vesting on the second anniversary of the grant date and 25% on the third and fourth anniversaries. This is an equity compensation award, not a market purchase, designed to align employee incentives with company performance.
MeiraGTx Holdings Plc Actuals & Estimates (FWB:328)
This article provides financial actuals and estimates for MeiraGTx Holdings Plc (FWB:328), including forecasted stock prices, historical highs and lows, and upcoming earnings dates. It details key financial metrics like earnings per share, revenue, net income, and EBITDA, and answers frequently asked questions about the company's stock.
MeiraGTx Holdings Plc Actuals & Estimates (SWB:328)
This article provides financial actuals and estimates for MeiraGTx Holdings Plc (SWB:328), including analyst forecasts, historical price data, earnings reports, revenue, net income, and EBITDA. It notes that the company does not pay dividends and details its employee count and upcoming earnings release date.
328 Forecast — Price Target — Prediction for 2027
This article provides a forecast for MeiraGTx Holdings Plc (328) stock, including analyst price targets and ratings. It details the company's financial metrics such as EPS, revenue, net income, and EBITDA, along with historical stock prices and upcoming earnings dates. The information is presented as a guide for potential investors, emphasizing the importance of personal research.
MeiraGTx Holdings Plc Actuals & Estimates (MUN:328)
This article provides an overview of MeiraGTx Holdings Plc (MUN:328) financials, including actual results, analyst estimates, and key statistics. It covers income statement, balance sheet, cash flow, earnings per share, revenue, net income, dividends, and EBITDA. The stock forecast indicates a max estimate of 43.34 EUR and a min estimate of 16.47 EUR from analysts.
328 Forecast — Price Target — Prediction for 2027
This article provides financial information and analyst forecasts for MeiraGTx Holdings Plc (ticker: 328 on FWB). It details the stock's price target, historical performance, earnings, revenue, EBITDA, and offers answers to frequently asked questions about the company. The content emphasizes that the information is not investment advice and encourages users to conduct their own research.
A2JGHF Forecast — Price Target — Prediction for 2027
The article provides a forecast and price target for MeiraGTx Holdings Plc (A2JGHF) based on analyst opinions, including maximum and minimum price estimates. It details the stock's recent performance, volatility, market capitalization, and upcoming earnings report. Additionally, it covers financial metrics such as EPS, revenue, net income, EBITDA, and dividend policy.
MeiraGTx Holdings Plc Actuals & Estimates (NASDAQ:MGTX)
This article provides financial actuals and estimates for MeiraGTx Holdings Plc (NASDAQ: MGTX), including its current stock price, historical performance, analyst forecasts, and upcoming earnings report. It highlights that the stock has seen significant increases over the last year, with analysts projecting a wide range for its future price. The company's recent financial results, including earnings per share and revenue, are also detailed, along with information on volatility, market capitalization, and employee count.
MGTX Forecast — Price Target — Prediction for 2027
This article provides a forecast for MeiraGTx Holdings plc (MGTX) stock, including analyst price targets, historical performance, and financial data. Analysts have a diverse price target range for MGTX, with a max estimate of $50.00 and a min estimate of $19.00. The company's current stock price, recent performance, key financial metrics, and upcoming earnings date are also detailed, along with a disclaimer that this is not investment advice.
MeiraGTx Holdings PLC (MGTX) Financial Health: Profitability & Balance Sheet Analysis
MeiraGTx Holdings PLC (MGTX) has a stable financial status with a score of 7.26, ranking 139th in its industry. Despite high operating efficiency, the company experienced an 84.79% year-over-year decrease in quarterly revenue and a 15.84% decrease in net profit. The lack of disclosed data for several financial aspects like cash flow and total assets suggests limited transparency in some areas of its financial reporting.
Diluted earnings per share (diluted EPS) of MeiraGTx Holdings Plc – DUS:328
This article provides a brief overview of the diluted earnings per share (diluted EPS) for MeiraGTx Holdings Plc, trading under the symbol DUS:328 on the Dusseldorf Stock Exchange. It highlights the company's financial information available on TradingView, indicating that specific EPS values are recorded under "Period," "Value," "Change," and "Change %" but these values are not displayed in the content provided.
Operating cash flow per share of MeiraGTx Holdings Plc – DUS:328
This article provides financial information for MeiraGTx Holdings Plc (DUS:328), specifically focusing on its operating cash flow per share. It is presented on the TradingView platform, which offers various financial tools and data. The content is primarily a listing of the company's financial overview without detailed analysis.
After tax other income/expense of MeiraGTx Holdings Plc – DUS:328
This article displays the "After tax other income/expense" financial metric for MeiraGTx Holdings Plc (DUS:328) on TradingView. It shows the period, value, and change associated with this metric, indicating the company's financial performance. The content is primarily a financial data point with no further commentary or analysis.
MeiraGTx Holdings Plc Balance Sheet – DUS:328
MeiraGTx Holdings Plc (DUS:328) reported its Q1 2026 financial position. Total assets decreased by 0.93% to 211.75 million EUR compared to Q4 2025, while total liabilities increased by 19.84% to 262.07 million EUR in the same period. The financial overview includes historical data for total assets, liabilities, and equity, presented annually and quarterly.
MeiraGTx Holdings Plc Revenue Breakdown – DUS:328
MeiraGTx Holdings Plc (DUS:328) generated €69.30 million in revenue last year, primarily from its Genetic Medicines segment. This marked a significant increase from €32.15 million in the prior year, with the United Kingdom being the largest contributor to revenue.
MeiraGTx Holdings PLC (MGTX) Institutional Confidence
MeiraGTx Holdings PLC (MGTX) has an institutional shareholding score of 5.00, placing it 133rd out of 389 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 59.59%, a 4.66% decrease quarter-over-quarter. Bill Nygren | OAKMX is the largest institutional shareholder, with 62.13K shares, despite an 84.48% decrease in holdings.
MeiraGTx Holdings PLC (MGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates
MeiraGTx Holdings PLC (MGTX) has an earnings forecast score of 8.50, ranking 108 out of 388 in its industry. Analysts have set an average price target of $27.00, with a high of $50.00 and a low of $15.00, predominantly recommending a "Buy" for the stock. The company's expected revenue for the next quarter is $15.66 million, and its EPS for the next quarter is projected at $-0.41.
MeiraGTx Holdings PLC (MGTX) Valuation: PE, PB & Fair Value Analysis
MeiraGTx Holdings PLC (MGTX) has a current valuation score of 9.46, placing it 32nd out of 388 companies in the Biotechnology & Medical Research industry. Its P/E ratio is -7.02, which is significantly below its recent high but slightly above its recent low. Key valuation metrics like P/B, P/S, and P/CF data have not yet been disclosed by the company.
MeiraGTx Holdings PLC (MGTX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides a detailed historical overview of dividends and stock splits for MeiraGTx Holdings PLC (MGTX). It notes that no dividends have been distributed in the past five years and no stock split data is available. The page also presents current stock performance data and an overview of market information for MGTX.
MeiraGTx Holdings PLC (MGTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for MeiraGTx Holdings PLC (MGTX), although it states that the relevant data for business segments, regional revenue, and profit contribution has not yet been disclosed by the company. It briefly shows the stock's current trading price and market capitalization. The article is hosted on TradingKey, a platform offering financial news, analysis, and tools.
MeiraGTx Shareholders Back Board Slate and Auditor Renewal
MeiraGTx Holdings plc shareholders recently re-elected three Class II directors to serve until 2029 and approved Ernst & Young LLP as the independent auditor for fiscal year 2026. This strong support from shareholders indicates confidence in the company's governance as it progresses with its gene therapy programs. TipRanks' AI Analyst, Spark, rates MGTX as Neutral, noting financial risks offset by improving cash flow and technical momentum.
Director at MeiraGTx (MGTX) receives 66,641 RSUs vesting in 2027
MeiraGTx Holdings plc Director Neil Mendoza was granted 66,641 Restricted Share Units (RSUs) on June 11, 2026. These RSUs will convert into ordinary shares upon settlement and are set to vest on the earlier of June 11, 2027, or the day before the company's 2027 annual shareholders' meeting. Mendoza has chosen for the RSUs to become settleable after he ceases to be a director, bringing his total reported RSU holdings to 66,641 units post-grant.
MeiraGTx (MGTX) investors back board slate and Ernst & Young
MeiraGTx Holdings plc shareholders approved the election of three Class II directors—Ellen Hukkelhoven, Ph.D., Nicole Seligman, and Debra Yu, M.D.—to serve until the 2029 annual meeting. Shareholders also ratified Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The annual general meeting, held on June 11, 2026, saw significant shareholder participation, with 81.4% of outstanding shares represented.
MeiraGTx Holdings plc Announces 2026 Annual Meeting Results and Auditor Appointment
MeiraGTx Holdings plc announced the results of its 2026 Annual General Meeting, held on June 11, 2026, with strong shareholder participation. Key outcomes included the re-election of three Class II directors and the ratification of Ernst & Young LLP as the company's independent auditor for the fiscal year ending December 31, 2026. These results signal stable governance and strong shareholder support, which are viewed favorably by the market, although no immediate price-sensitive corporate actions were disclosed.
MeiraGTx (MGTX) director Harris Keith R. granted 106,441 restricted share units
MeiraGTx (MGTX) director Harris Keith R. has been granted 106,441 restricted share units (RSUs) as equity compensation on June 11, 2026. These RSUs will vest in a single installment on the earlier of June 11, 2027, or the day before the company's 2027 annual shareholder meeting. Following this grant, Harris Keith R. directly holds 106,441 restricted share units, with each unit convertible into one ordinary share upon settlement.
Director Debra Yu awarded 60,000 MeiraGTx (MGTX) restricted share units
MeiraGTx Holdings plc director Debra Yu was granted 60,000 restricted share units (RSUs) as stock-based compensation. These RSUs will convert into ordinary shares upon settlement and are scheduled to vest on the earlier of June 11, 2027, or the day before the 2027 annual shareholder meeting. Yu has elected to have the RSUs settle when she ceases to be a director, and after this grant, she holds 60,000 RSUs directly.
MeiraGTx (MGTX) director receives 69,662 RSUs vesting in 2027
MeiraGTx (MGTX) director Thomas E. Shenk was granted 69,662 restricted share units (RSUs). These RSUs will vest in a single annual installment on the earlier of June 11, 2027, or the day before the company's 2027 annual meeting of shareholders. Shenk elected for the RSUs to become settleable upon his cessation as a director.
[Form 4] MeiraGTx Holdings plc Insider Trading Activity
MeiraGTx Holdings plc director Ellen Hukkelhoven was granted 60,000 Restricted Share Units (RSUs) as a compensation-related award with no cash price per unit. These RSUs convert into ordinary shares upon settlement and will vest on the earlier of June 11, 2027, or the day before the company's 2027 annual shareholder meeting. Hukkelhoven elected for the RSUs to become settleable when she ceases to be a director.
MeiraGTx shareholders elect directors and approve auditor at annual meeting
MeiraGTx Holdings plc shareholders held their annual general meeting, electing three Class II directors to serve until 2029 and ratifying Ernst & Young LLP as their independent public accounting firm for the fiscal year ending December 31, 2026. The company also recently completed a strategic collaboration with Hologen Limited for gene therapies and priced a public offering to raise approximately $100 million. Analysts have maintained positive outlooks on MeiraGTx, citing strong data for its xerostomia treatment and strategic reacquisition of bota-vec.
MeiraGTx (MGTX) director converts 75,000 RSUs, boosting holdings to 200,000 shares
MeiraGTx Holdings plc director Harris Keith R. converted 75,000 restricted share units (RSUs) into 75,000 ordinary shares without a reported purchase price. This transaction increased his direct holdings to 200,000 ordinary shares. The conversion, detailed in a Form 4 SEC filing, represents a routine equity settlement rather than an open-market trade.
